Detalles de la búsqueda
1.
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
Lancet
; 384(9960): 2111-22, 2014 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-25189359
2.
Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial.
Am Heart J
; 168(3): 256-61, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25173535
3.
Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design.
Am Heart J
; 163(2): 136-41.e1, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22305828
4.
Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II.
PLoS One
; 14(1): e0210821, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30645635
5.
A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial.
EuroIntervention
; 14(6): 692-699, 2018 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29205157
6.
Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
J Am Heart Assoc
; 5(3): e003255, 2016 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26979080
7.
A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy.
Cardiovasc Revasc Med
; 17(6): 355-61, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27156201
8.
Angiographic complexity of coronary artery disease according to SYNTAX score and clinical outcomes after revascularisation with newer-generation drug-eluting stents: a substudy of the BIOSCIENCE trial.
EuroIntervention
; 12(5): e595-604, 2016 Aug 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27497359
9.
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction.
EuroIntervention
; 12(11): e1343-e1354, 2016 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26690319
10.
Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial.
Circ Cardiovasc Interv
; 8(6)2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26043895
11.
N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Eur J Heart Fail
; 15(10): 1148-56, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23657728
12.
Multidisciplinary Assessment to Personalize Length of Stay in Acute Decompensated Heart Failure (OPTIMA II ADHF).
J Clin Med Res
; 4(6): 402-9, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23226173
13.
Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction: Insights From the 2-Year Follow-Up of the BIOSCIENCE Trial.
JACC Cardiovasc Interv
; 9(9): 981-3, 2016 05 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27151616
Resultados
1 -
13
de 13
1
Próxima >
>>